Evidence of retinal arteriolar narrowing in patients with autosomal-dominant polycystic kidney disease
, , , , , , , , , und | 09. März 2022
Über diesen Artikel
Article Category: Original Study
Online veröffentlicht: 09. März 2022
Seitenbereich: 82 - 90
Eingereicht: 03. März 2021
Akzeptiert: 17. Nov. 2021
DOI: https://doi.org/10.2478/ahem-2022-0001
Schlüsselwörter
© 2022 Maria Pietrzak-Nowacka et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Multivariate analysis including AVR as dependent variable and group (ADPKD patients vs controls), age, gender, eGFR and presence of hypertension as independent variables
| Independent variables | Coefficient in regression equation | Standardized beta | p-value |
|---|---|---|---|
| Group (ADPKD vs controls) | −0.069 | −0.502 | |
| Gender (male vs female) | −0.24 | −0.171 | |
| Age (years) | 0.00056 | 0.083 | 0.37 |
| Hypertension | 0.0052 | 0.037 | 0.7 |
| eGFRCKD EPI (mL/min/1.73m2) | 0.0026 | 0.076 | 0.44 |
The values of ocular and macro- and micro-retinal vessel parameters in ADPKD patients and the control group
| Parameter | ADPKD group (n=76 eyes) | Control group (n=90 eyes) | p-value |
|---|---|---|---|
| AVR | 0.806 ± 0.064 (0.81) | 0.876 ± 0.056 (0.88) | |
| DVA A [%] | 3.32 ± 2.15 (3.3) | 3.37 ± 2.00 (3.2) | 0.78 |
| DVA V [%] | 3.72 ± 2.18 (3.3) | 4.31 ± 2.38 (4) | 0.096 |
| IOP values (mmHg) | 17.2 ± 2.27 (17.4) | 17.8 ± 0.98 (17.7) | 0.35 |
| OPA (mmHg) | 2.71 ± 1.017 (2.5) | 2.93 ± 0.97(2.75) | 0.18 |
| MOPP (mmHg) | 52.11 ± 6.25 (52.03) | 46.77 ± 7.43 (46.77) |
Grading of retinopathy in ADPKD patients and control group according to the Keith-Wagener classification
| Group | ADPKD group (n=73 eyes) | Control group (n=90 eyes) | p-value |
|---|---|---|---|
| No retinopathy | 32 (44%) | 75 (83%) | reference |
| Grade I (AN) | 33 (45%) | 12 (13%) | <0.00001 |
| Grade II (AVC) | 8 (11%) | 3 (3%) | 0.0070 |
Clinical and biochemical characteristics of the ADPKD and control groups. Data are presented as the mean ± SD (median) or number (percentage) of patients with a particular feature
| Parameter | ADPKD group (n=38) | Control group (n=45) | p-value |
|---|---|---|---|
| Age (years) | 43.6 ± 11.6 (44) | 43.71 ± 9.11(41) | 0.87 |
| Male gender (%) | 14 (37%) | 20 (44%) | 0.51 |
| BMI (kg/m2) | 27.3 ± 5.3 (27.1) | 25.7 ± 4.3 (25.4) | 0.26 |
| Hypertension | 22 (67%) | 7 (16%) | |
| SBP (mmHg) | 135 ± 12.9 (132) | 126±13.9 (125) | |
| DBP (mmHg) | 89 ± 9.34 (88) | 82.6±10.7 (83.0) | |
| MAP | 104 ±9.043 (103.3) | 97.04±10.9 (97) | |
| TC (mg/dL) | 219 ± 36.7 (222) | 218 ±39.1 (212) | 0.91 |
| LDL (mg/dL) | 133 ± 28.1 (129) | 127 ± 37.4 (117.5) | 0.26 |
| HDL (mg/dL) | 56.2 ± 11.5 (56) | 58.02 ± 13.7 (58) | 0.61 |
| TG (mg/dL) | 116 ± 56.4 (102) | 120 ± 99.2 (97) | 0.504 |
| Fasting glucose (mg/dl) | 92.6 ± 13.1 (89.5) | 95.0 ± 13.6 (94) | 0.22 |
| Fasting insulin (μU/ml) | 11 ± 10.5 (7.2) | 12.1 ± 14.1 (7.9) | 0.68 |
| HbA1C (%) | 5.2 ± 0.33 (5.2) | 5.34 ± 0.56 (5.2) | 0.77 |
| HOMA%S | 61.8 ± 40.3 (61.83) | 69.6 ± 56.9 (53.65) | 0.94 |
| HOMA%B | 132 ± 74.01 (109.4) | 133 ± 115 (96) | 0.26 |
| Urea (mg/dL) | 37.1 ± 16.9 (33.5) | 28.2 ± 8.61 (27.5) | |
| Uric acid (mg/dL) | 6.34 ± 1.94 (6.2) | 5.43 ± 1.39 (5.35) | |
| Creatinine (mg/dL) | 1.084 ± 0.58 (0.97) | 0.82 ± 0.12 (0.82) | |
| eGFRCKD EPI (mL/min/1.73m2) | 81.3 ± 26.3 (84.05) | 98.4 ± 11.6 (98.7) |